Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Non-Current Assets (2023 - 2025)

Mangoceuticals' Non-Current Assets history spans 3 years, with the latest figure at $15.9 million for Q3 2025.

  • For Q3 2025, Non-Current Assets rose 8.48% year-over-year to $15.9 million; the TTM value through Sep 2025 reached $15.9 million, up 8.48%, while the annual FY2024 figure was $15.3 million, 7001.0% up from the prior year.
  • Non-Current Assets for Q3 2025 was $15.9 million at Mangoceuticals, down from $20.7 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $21.6 million in Q1 2025 and bottomed at $211639.0 in Q1 2024.
  • The 3-year median for Non-Current Assets is $14.7 million (2024), against an average of $9.5 million.
  • The largest annual shift saw Non-Current Assets fell 27.72% in 2024 before it soared 10095.29% in 2025.
  • A 3-year view of Non-Current Assets shows it stood at $215391.0 in 2023, then surged by 7001.0% to $15.3 million in 2024, then grew by 4.18% to $15.9 million in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Non-Current Assets are $15.9 million (Q3 2025), $20.7 million (Q2 2025), and $21.6 million (Q1 2025).